NCT00647530 (FOxTROT) is a Phase 2, PHASE3 clinical trial of panitumumab in Colorectal Cancer, sponsored by University of Birmingham.

Who is sponsoring NCT00647530?

NCT00647530 is sponsored by University of Birmingham.

What drugs are being tested in NCT00647530?

Interventions in NCT00647530: panitumumab, capecitabine, fluorouracil, oxaliplatin.

What condition does NCT00647530 study?

NCT00647530 studies Colorectal Cancer.

Is NCT00647530 still recruiting?

NCT00647530 is currently status unknown. Last updated 17 May 2019.

Last reviewed 2019-05-17 · How we verify

NCT00647530: FOxTROT

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Fluorouracil and Oxaliplatin With or Without Panitumumab In Treating Patients With High-Risk Colon Cancer That Can Be Removed by Surgery

Status unknown Phase 2, PHASE3 Last updated 17 May 2019

What this trial tests

Phase 2, PHASE3 trial testing panitumumab in Colorectal Cancer in 1,053 participants. Status unknown.

Timeline

15 May 2008

Primary endpoint
23 December 2016

31 December 2019

Quick facts

Lead sponsor	University of Birmingham
Phase	Phase 2, PHASE3
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	1,053
Start date	15 May 2008
Primary completion	23 December 2016
Estimated completion	31 December 2019
Sites	10 locations across United Kingdom

Drugs / interventions tested

panitumumab
capecitabine (capecitabine) — full drug profile →
fluorouracil — full drug profile →
oxaliplatin (Oxaliplatin) — full drug profile →

Conditions studied

Colorectal Cancer — all drugs for Colorectal Cancer →

Sponsor

University of Birmingham

Who can join

18 and older, any sex, with Colorectal Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

RATIONALE: Drugs used in chemotherapy, such as fluorouracil and oxaliplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as panitumumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Giving chemotherapy before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. Giving chemotherapy after surgery may kill any tumor cells that remain after surgery. It is not yet known whether chemotherapy is more effective with or without panitumumab in treating patients with colon cancer. PURPOSE: This randomized phase III trial assessing whether preoperative chemotherapy and/or an anti-EGFR monoclonal antibody improve outcome in high risk operable colon cancer.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Preoperative Chemotherapy for Operable Colon Cancer: Mature Results of an International Randomized Controlled Trial.
Morton D, Seymour M, Magill L, Handley K, et al · · 2023 · cited 285× · PMID 36657089 · DOI 10.1200/jco.22.00046
Dynamic and adaptive cancer stem cell population admixture in colorectal neoplasia.
Vasquez EG, Nasreddin N, Valbuena GN, Mulholland EJ, et al · · 2022 · cited 96× · PMID 35931031 · DOI 10.1016/j.stem.2022.07.008
Early stage colon cancer: Current treatment standards, evolving paradigms, and future directions.
Chakrabarti S, Peterson CY, Sriram D, Mahipal A. · · 2020 · cited 89× · PMID 32879661 · DOI 10.4251/wjgo.v12.i8.808
Neoadjuvant Chemotherapy without Radiation in Colorectal Cancer.
Bhudia J, Glynne-Jones R, Smith T, Hall M. · · 2020 · cited 9× · PMID 32968364 · DOI 10.1055/s-0040-1713746
Immunotherapy for Early Stage Colorectal Cancer: A Glance into the Future.
Cohen R, Shi Q, André T. · · 2020 · cited 9× · PMID 32708216 · DOI 10.3390/cancers12071990
Risk of Bowel Obstruction in Patients Undergoing Neoadjuvant Chemotherapy for High-risk Colon Cancer: A Nested Case-control-matched Analysis of an International, Multicenter, Randomized Controlled Trial (FOxTROT).
FOxTROT Collaborating Group. · · 2024 · cited 7× · PMID 37947140 · DOI 10.1097/sla.0000000000006145
Evaluating the oncological safety of neoadjuvant chemotherapy in locally advanced colon carcinoma: a systematic review and meta-analysis of randomised clinical trials and propensity-matched studies.
Davey MG, Amir AH, Ryan OK, Donnelly M, et al · · 2023 · cited 7× · PMID 37432559 · DOI 10.1007/s00384-023-04482-x
A panel of DNA methylation markers for the classification of consensus molecular subtypes 2 and 3 in patients with colorectal cancer.
van den Berg I, Smid M, Coebergh van den Braak RRJ, van de Wiel MA, et al · · 2021 · cited 6× · PMID 34510716 · DOI 10.1002/1878-0261.13098

Verify or expand the search:

Other trials of panitumumab

Trials testing the same drug.

NCT07094204 — A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors · Phase 1 · recruiting
NCT06714357 — ValproIc Acid to Potentiate Anti-EGFR Treatment Efficacy and Prevent/Revert Resistance in Colorectal Cancer · Phase 2 · recruiting
NCT01814501 — Panitumumab and Chemotherapy in Patients With Advanced Colorectal Cancer After Prior Therapy With Bevacizumab · Phase 2 · completed
NCT01312857 — Study of Hepatic Arterial Infusion With Intravenous Irinotecan, 5FU and Leucovorin With or Without Panitumumab, in Patie · Phase 2 · completed
NCT00820248 — Radiation + Cisplatin or Panitumumab in Locally Advanced Stage III or Stage IV Head and Neck Cancer · Phase 3 · completed

Other recruiting trials for Colorectal Cancer

Currently open trials in the same condition.

NCT07152821 — Botensilimab + Balstilimab vs Best Supportive Care as Therapy in Chemo-refractory, Unresectable, Colorectal Adenocarcino · Phase 3 · recruiting
NCT07353645 — KRAS Neoantigen Nanovaccine as Adjuvant Therapy for Colorectal Cancer/Pancreatic Cancer · Phase 1, PHASE2 · recruiting
NCT07432633 — [18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications · Phase 1, PHASE2 · recruiting
NCT07523919 — Functional and Respiratory Determinants of Long-Term Colorectal Cancer Outcomes · recruiting
NCT07529301 — Functional and Respiratory Predictors of Early Postoperative Outcomes · recruiting

Other University of Birmingham trials

Trials by the same sponsor.

NCT07160686 — Apixaban to Prevent Venous Thromboembolism in Ambulatory Lung Cancer Patients Undergoing Systemic Anticancer Treatment · Phase 3 · not yet recruiting
NCT07446166 — TETANUS Antibody Detection in Saliva Study · NA · not yet recruiting
NCT07294794 — Personalised Pharmacometabolomic-guided Strategy Trial to Optimise Treatment for Hypertension · NA · not yet recruiting
NCT07246356 — Feasibility and Efficacy of GTEP for Birth Trauma · NA · recruiting
NCT06932653 — Reducing Deaths After Surgery in Low- and Middle-income Countries: A Pilot Cluster Randomised Trial · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00647530 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Birmingham
Last refreshed: 17 May 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00647530.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing